Profil
Zemer Gitai currently works at ArrePath, Inc., as Director.
Aktive Positionen von Zemer Gitai
| Unternehmen | Position | Beginn |
|---|---|---|
ArrePath, Inc.
 ArrePath, Inc. Information Technology ServicesTechnology Services ArrePath, Inc. is an anti-infective drug discovery company that focuses on addressing the health challenge of drug-resistant infections. The platform's proof-of-concept has been demonstrated in studies published in Cell by ArrePath's scientific founder, Zemer Gitai, Ph.D., Edwin Grant Conklin Professor of Biology at Princeton University. The company is based in Princeton, NJ, and is funded by the Boehringer Ingelheim Venture Fund, Insight Partners, Innospark Ventures, Viva BioInnovator, Arimed Capital, PTX Capital, and Nor'easter Ventures. The company utilizes a proprietary machine learning-based platform to efficiently identify anti-infective agents with new mechanisms of action at the outset of the discovery process. This is achieved through a deep understanding and analysis of pathogen behavior. The CEO of the company is Lloyd J. Payne. | Direktor/Vorstandsmitglied | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 1 |
|---|---|
ArrePath, Inc.
ArrePath, Inc. Information Technology ServicesTechnology Services ArrePath, Inc. is an anti-infective drug discovery company that focuses on addressing the health challenge of drug-resistant infections. The platform's proof-of-concept has been demonstrated in studies published in Cell by ArrePath's scientific founder, Zemer Gitai, Ph.D., Edwin Grant Conklin Professor of Biology at Princeton University. The company is based in Princeton, NJ, and is funded by the Boehringer Ingelheim Venture Fund, Insight Partners, Innospark Ventures, Viva BioInnovator, Arimed Capital, PTX Capital, and Nor'easter Ventures. The company utilizes a proprietary machine learning-based platform to efficiently identify anti-infective agents with new mechanisms of action at the outset of the discovery process. This is achieved through a deep understanding and analysis of pathogen behavior. The CEO of the company is Lloyd J. Payne. | Technology Services |
